Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GRN | P28799 | 1/20 | 0.47 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.47 |
| ▸ | KCNT1 | Q5JUK3 | 13/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | KCNMB1 | Q16558 | 1/20 | 0.44 |
| ▸ | KCNT2 | Q6UVM3 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20646935 | 0.85 | GRN (0.67) | KDM4EGRNSORT1RAB9ACTSL | |
| SCHEMBL13064210 | 0.81 | KDM4E (0.51) | KDM4EGRNSORT1KCNT1ALDH1A1 | |
| SCHEMBL17920 | 0.81 | GRN (0.71) | KDM4EGRNSORT1KCNT1ALDH1A1 | |
| SCHEMBL17732 | 0.79 | KDM4E (0.50) | KDM4EGRNSORT1KCNT1ALDH1A1 | |
| SCHEMBL951323 | 0.79 | KDM4E (0.50) | KDM4EGRNSORT1KCNT1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL8932269 | 0.79 | GRN (0.69) | KDM4EGRNSORT1KCNT1ALDH1A1 | |
| SCHEMBL30305711 | 0.78 | KDM4E (0.49) | KDM4EGRNSORT1KCNT1ALDH1A1 | |
| SCHEMBL13020360 | 0.78 | KDM4E (0.53) | KDM4EGRNSORT1KCNT1ALDH1A1 | |
| SCHEMBL19994223 | 0.77 | KDM4E (0.47) | KDM4EGRNSORT1KCNT1ALDH1A1 | |
| SCHEMBL19902317 | 0.77 | ALDH1A1 (0.50) | KDM4EGRNSORT1KCNT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3954681-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2022-02-16 | — | — | EP | disclosed |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, LRAT | KDM4E 4674/4885GRN 728/4885SORT1 225/4885 |
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | KDM4E 2298/4885GRN 4138/4885SORT1 1705/4885 |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | ROCK1, MYLK, RHOA | KDM4E 2298/4885GRN 4138/4885SORT1 1705/4885 |
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | KDM4E 1546/4885GRN 3888/4885SORT1 3298/4885 |
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | KDM4E 1546/4885GRN 3888/4885SORT1 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.